Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
July 1, 2021 Great news!
Article Link below excerpt :
CEO Dr. Arthur Mikaelian. "We hope that those who follow our company see how quickly we are moving in this process since receiving our response from the FDA. These programs generally take years and we have wasted no time since receiving the guidelines in preparing for our next steps. We are extremely confident in Escozine's potential palliative and therapeutic benefits and look forward to updating those interested as soon as possible."
https://www.google.com/amp/s/www.barrons.com/amp/articles/medolife-rx-announces-successful-stability-results-on-escozine-conjugated-with-radioactive-iodine-01625142673
https://www.edencap.com/
Impressive … the potential here just seems more exponential the more the details come to light … this company has taken seemingly great pragmatic moves to ensure a strong foundation utilizing smart mergers and creating smart collaborations
… I’m waiting patiently as I’m really long on this company… stable long standing companies didn’t happen overnight, thank you Dragon Lady for all the informative posts … the patents, science, scorpion ranch, and yes, retail products too, all combined together make this what I believe to be a huge (potential) Win!!
That is, In my opinion of course, i $hare the optimism with many others here
Happy July everyone - here’s to 2021 being a huge break out year for QNTA
Skateboarding Legend Tony Hawk Teams Up With AELIA!
AELIA, the worlds highest powered pain and muscle rub has partnered with Tony Hawk, the worlds highest powered extreme sports legend. At AELIA we have harnessed the energy of quantum polarization technology and natural ingredients to create the fastest and most effective muscle relief and workout recovery product on the market. From the most elite athlete like Tony Hawk to the weekend warrior, with AELIA we’ve got your back…and knees, and elbows!
https://aeliastore.com/tony-hawk/
Medolife Rx Announces Successful Stability Results on Escozine Conjugated With Radioactive Iodine
Quanta, Inc.
Thu, July 1, 2021, 8:30 AM·6 min read
https://finance.yahoo.com/news/medolife-rx-announces-successful-stability-123000414.html
:) the support they get from the Dominican Republic is great! Why? Because both the DR & Medolife will prosper through QNTA succe$$
Another great read / reminder …
https://www.morningstar.com/news/globe-newswire/8238254/medolife-rx-ceo-receives-achievement-award-from-regulatory-agency-in-the-dominican-republic-for-work-on-covid-19-treatment
Keeping my eye on the prize ;)
Decades of research are finally on the edge of being fda and DR approved … paytience they are following all the steps required…
[{“The response validated the Company’s clinical study conducted in the Dominican Republic (DR) and outlined next steps for its approval process in the US.
As the Company expected, it received a detailed response from the FDA on its Pre-IND originally filed on April 27, 2020. The response included: recognition from the FDA on the therapeutic effects of Escozine®, validation of the Company’s clinical trial as an informal proof-of-concept study, and laid out very specific guidelines for the next steps required by the regulatory body in order to garner approval for Escozine® as a treatment for COVID-19.”}] https://finance.yahoo.com/news/fda-accepts-covid-19-clinical-123000620.html
Happy $ixth of July to you too ;)
Bio space is a Great place for news gathering regarding QNTA https://www.biospace.com/news/?Keywords=Qnta
Here’s a big part of the “why” I’m still very much long QNTA (it’s worth the read or Reread in many cases .. link at bottom of article source)
[{“A recent Business Insider article estimated scorpion venom to be the most expensive liquid in the world, valued at $39 million dollars-per-gallon. Scorpion venom is currently in active research by large pharmaceutical companies for its therapeutic use in treating cancer, COVID-19, viral diseases, inflammation, and pain, all of which are independently multi-billion-dollar industries. Medolife is a pioneer in venom-to-drug development. With Medolife's Dominican Republic Scorpion Reservation being one of the largest natural breeding grounds for scorpions on earth. Medolife will bring its 30+ years of research and expertise to help locate, study and develop groundbreaking formulas and pharmaceutical-grade medications for consumer use. This agreement also allows for Medolife to expand its existing infrastructure, facilities, and certified pharmaceutical lab.
Medolife's close relationship with the Dominican Republic government dates back to 2007, which significantly contributed to research and FDA trials of a new generation of natural pharmaceutical-grade and evidence-based nutraceutical products. Medolife CEO, Dr. Arthur Mikaelian said "We could not feel more humbled by the trust the Dominican Republic Government has shown to us. We have worked closely with them for the past 14 years and are incredibly excited to continue our research and trials with them as a partner for the next 10-years and beyond." He continued by saying "This partnership has the possibilities to bring so many new life-changing formulas to the world. From cancer medications to viral and immune system therapies, we are truly just scratching the surface of what this incredible peptide can do for mankind."
Over the years, The Government of The Dominican Republic and Medolife have undertaken extensive research and expeditions to locate and identify specific scorpion species that have therapeutic and medical values. Marina Hernandez, Head of the Genetic Resources Department of the Biodiversity Directorate with the Dominican Republic Ministry of Environment said "A long term partnership between our Government and Medolife gives us much hope. We have experienced first-hand the marvelous results Dr. Mikaelian has discovered through his research. With our ongoing support of Medolife's research, we wish to contribute to the significant improvement of the lives of people in the Dominican Republic, and the world at large."
https://www.biospace.com/article/releases/medolife-rx-inc-has-submitted-applications-of-their-scorpion-venom-to-help-fight-against-cancer-and-covid-19-with-the-fda-in-the-dominican-republic-/
Good morning Qnta longs!! 8:30a ET 6/29/2021 - Globe Newswire
Medolife Rx Enters Partnership Agreement with Leading International Distributor, Brings Products to Mexico
Mentioned: QNTA
via NewMediaWire - Medolife Rx, Inc. ("Medolife"), a global integrated biopharmaceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today that it entered into a partnership agreement with Xoles Del Pacifico, S.A. De C.V. (Xoles) a leading international distributor of pharmaceutical and wellness products, to bring Medolife's consumer brands to the Mexican market. Products to be sold in Mexico through the agreement include Medolife's Immunapen(TM) product line, as well as its cannabidiol (CBD) and non-CBD line of pain relief/muscle creams. Additionally, Medolife will use its patented polarization technology to enhance existing over-the-counter (OTC) pharmaceutical-grade white label products, such as male enhancement products and vitamins.
The exclusive partnership agreement grants Xoles the sole opportunity to market and sell Medolife's proprietary product line throughout Mexico through its broad network with thousands of retail locations, as well as through various direct-to-consumer e-commerce channels. Xoles has strong relationships throughout the country with the largest drugstore chains and global big box retailers. Distribution will include Medolife's leading product line, called Immunapen(TM), that includes four formulations specifically designed to promote general wellness aspects of consumers' lives such as sleep, immunity support, anti-anxiety, and energy and focus. This product line was created in response to the COVID-19 pandemic to address health concerns revolving around immunity, stress, anxiety and lack of energy. The Immunapen(TM) product line contains a natural version of the peptides used in the Company's lead drug candidate Escozine(R) that are amplified by Medolife's proprietary polarization technology. Additionally, through the partnership, the two companies will collaborate on development of additional topical pain management products utilizing the company's polarization technology that increases the efficacy of known natural compounds.
Beyond the Immunapen(TM) product line, the agreement includes the sale and distribution of the Company's core wellness products that include hemp-based CBD brands, which have also been polarized to increase potency and efficacy. The first products to enter Mexico will be the CBD Muscle and Pain cream, with additional products following shortly, including tinctures and sprays. The CBD market has continued to grow exponentially in recent years, with consumer adoption at all-time highs. The Mexican market presents a unique opportunity for the Company as it is less saturated than other more established markets, giving Medolife first-mover advantage through this relationship.
"We have been working on this agreement for some time now and I could not be more pleased to see it signed and take effect," said Medolife CEO Dr. Arthur Mikaelian. "We have such a strong portfolio of products and continue to look for partners who have the experience in select markets to capitalize on them. We have found just that in working with Xoles. Beyond their extensive retail distribution footprint, they understand the needs of consumers in the Mexican market, and, more importantly, how to reach them with the unique message of our products. We hope that this relationship proves fruitful for both of our companies as well as consumers in Mexico."
The Company has been working on rebranding its nutraceutical division in recent months and hopes to launch this new branding in the near term. It will retain the rights to market and sell its products throughout the United States, while seeking partnerships and joint ventures around the world to expedite their distribution and make a global impact.
Beyond its wellness products, Medolife has clinical initiatives taking place in both the United States and the Dominican Republic (DR) on its lead drug candidate, Escozine(R). Escozine(R) also utilizes a patented polarization technology developed by Dr. Mikaelian that increases the potency of single molecules and complex compounds, in this case peptides derived from scorpions. The Company has been scaling production of both its wellness and nutraceutical products as it recently renewed its product registration in the DR on Escozine(R) as a natural alternative treatment for various forms of cancer. It has also completed a PRE-Investigational New Drug (PIND) filing on Escozine(R), through the US Food and Drug Administration (FDA), and is awaiting a response on the submission of its final data set.
About Medolife Rx
Medolife Rx, Inc. is a global biotechnology company with operations in clinical research, manufacturing, and consumer products. Medolife Rx was created through the merger of Medolife, a private company founded by Dr. Arthur Mikaelian who pioneered the unlaying polarization technology that makes the Company's portfolio of pharmaceutical and nutraceutical products so effective, and Quanta, Inc., a direct-to-consumer wellness product portfolio company. The Company's lead clinical development programs include Escozine(R), a proprietary formulation consisting of small molecule peptides derived from Rhopalurus princeps scorpions, which is amplified by the Company's polarization technology and is being researched as a treatment of various indications, including COVID-19 and cancer. The Company has completed preclinical safety and efficacy research on Escozine(R) and is pursuing product registration and drug approval in various countries, including the United States and throughout Latin America.
Through its subsidiary QuantRx, Medolife manufactures and distributes consumer wellness products in high-impact consumer areas such as pain relief, beauty, and general wellness. QuantRx products are designed using Dr. Mikaelian's polarization technology, which applies advances in quantum biology to increase the potency of active ingredients. Ultimately, Quanta's mission is to deliver better, more effective ingredients to elevate product efficacy, reduce waste, and facilitate healthier, more sustainable consumption.
Beyond its own clinical and consumer applications, the polarization technology used by Medolife and its subsidiaries has many potential applications. From potentiating bio-ingredients, to producing more-effective carbon-trapping plants, to transformative anti-aging solutions, Medolife has the opportunity to upend how commercial and pharmaceutical products are made and increase their benefits, while decreasing their chemical concentration.
Forward-Looking Statements
Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995: This release contains statements that are forward-looking in nature which express the beliefs and expectations of management including statements regarding the Company's expected results of operations or liquidity; statements concerning projections, predictions, expectations, estimates or forecasts as to our business, financial and operational results and future economic performance; and statements of management's goals and objectives and other similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "estimate," "plan," "project," "continuing," "ongoing," "expect," "we believe," "we intend," "may," "will," "should," "could," and similar expressions. Such statements are based on current plans, estimates and expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. These factors and additional information are discussed in the Company's filings with the Securities and Exchange Commission and statements in this release should be evaluated in light of these important factors. Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
Contacts:
Tom Nelson
https://ir.quantrx.com/
480-326-8577
Kyle Porter
medolife@cmwmedia.com
858-264-6600
https://ml.globenewswire.com/media/dbe8fad7-b222-45ce-92ef-446b52583d6e/small/quanta-logo-png.png
https://ml.globenewswire.com/media/dbe8fad7-b222-45ce-92ef-446b52583d6e/small/quanta-logo-png.png
For whatever reason Your “sup all” comment conjured my mind to recall the last scene in the movie Trading Places …
Let’s hope it’s a fortuitous thought :)
Fda asked for data on how it affects at the dna level …. Things are still very much in forward motion ..
I concur …
Ticker is supposed to change, product is available to ship July 5 … why market the heck out of something that’s changing name and shipping soon .. advertising “available now” makes more sense .. we are all privy to the what and The Who in regards to product and endorsement we just have to be paytient for the when $$$
The product site shows ordered items available July 5.. Until then, I would not expect any heavy promoting until that date … we know who they’ve signed - Tony Hawk, who makes sense for advertising muscle rub to an extremely wide audience spread in regards to all ages / demographics. Personally, while I’d love to see the advertising now - it only makes sense to hold back until products are ready to ship :)
I think finding other forums to bring things up is helpful… for example on a face book page article that brings up covid / medicine etc … find a legitimate Segway to post a relevant article with the QNTA ticker tagged and help promote the company we all have a vested interest in … I started up a conversation about the muscle rub saying Tony Hawk is going to make muscle rub cool for the grey haired 50s 60s crowd. A guy chimed in saying he had motor power skate boards and too was grey haired etc. so I then shared a bunch of great QNTA research … if any one on this board is into extreme sports and is on face book there’s a lot of “over 40”. “Over 50” etc groups out there
At this point having valid discussion with folks will help - and ultimately some one else might see all the good that we all see and happily benefit from buying in early too. Ive quietly bought and sold various stocks for years - legitimately this is the first one I’ve ever bothered to comment on publicly. Either we are all wrong and I’ll loose a ton … ORRRRR we are all correct in our faith in what we’ve researched and read .. the QNTA data / science / patents / smart mergers / aligning themselves with the DR Govt in order to benefit the countries citizens … how could any one not cheer for them to be successful?
Paytience I believe will pay $
I’d say, the FDA request is not a punt but rather a window into covid 19 vaccines and what the fda has learned thus far.. this article I’m sharing a link of shows they are raising the bar so to speak to every applicant … if as an investor one believes in QNTA, their science / data, and products .. the fda push back is just a delay PAYTIENCE $$$ https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-action-help-facilitate-timely-development-safe-effective-covid
Escozine a cancer treatment/ therapeutic found to Also have great results combating covid 19 … covid 19 is far from gone, it’s mutating, and like the flu, unfortunately, lots of varieties will likely continue to surface … anyone who thinks QNTA is a flash in the Pan covid stock has clearly Not Done any serious reading about the company - so much science & extremely promising data E$COZINE is extremely PROMI$ING in my opinion
Good luck to all … I’m long on this
https://www.globenewswire.com/fr/news-release/2021/04/01/2203353/0/en/Medolife-Rx-s-Lead-Drug-Candidate-Escozine-Recommended-by-Doctor-for-Use-in-Cancer-Treatment-Regimen-in-Dominican-Republic.html
I’m Sharing your optimism!!! $$$
as it’s all backed by lots of pragmatic DD
the science portfolio of QNTA is sound and mighty impressive … nice to have the camaraderie on this board and so many adding to the list of pertinent company information. QNTA MedolifeRX AELIA etc
All great!!
Excerpt from yesterday’s news [{“DiArcangelo has 24 years of experience in the global biotechnology, pharmaceutical, device, and nutraceutical industries and has worked on products that have received FDA approval on 25 pharmaceutical drugs.”}]
… paytience $$$
Yesterdays News in it’s entirety below, to me, it was worth rereading as they are clearly on top of things:
[{ 8:30a ET 6/23/2021 - Globe Newswire
FDA Accepts COVID-19 Clinical Study and Advises on Next Steps for Pre-IND Filing by Medolife Rx
Mentioned: QNTA
via NewMediaWire - Medolife Rx, Inc. ("Medolife"), a global integrated biopharmaceutical company with R&D, manufacturing, and consumer products, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today that the Company has received a response from the U.S. Food and Drug Administration (FDA) relating to its Pre-Investigational New Drug (Pre-IND) filing on its lead drug candidate Escozine(R) for the treatment of the SARS-CoV-2 (COVID-19) virus. The response validated the Company's clinical study conducted in the Dominican Republic (DR) and outlined next steps for its approval process in the US.
As the Company expected, it received a detailed response from the FDA on its Pre-IND originally filed on April 27, 2020. The response included: recognition from the FDA on the therapeutic effects of Escozine(R), validation of the Company's clinical trial as an informal proof-of-concept study, and laid out very specific guidelines for the next steps required by the regulatory body in order to garner approval for Escozine(R) as a treatment for COVID-19.
Subsequent to the acknowledgement of the trial, the FDA has requested that the Company complete two additional toxicology studies in animals. Since adoption of COVID-19 vaccinations, the FDA altered its protocol for measuring toxicology to include studying it at the DNA level. As this is a newer development, the agency has asked Medolife to provide data in this regard. Medolife has the product and protocol necessary to complete these studies in short-order.
"We could not be more pleased with the response from the FDA, in its acknowledgment of our clinical trials on Escozine and its potential therapeutic benefit, as well as the very clear guidelines set forth in the response for moving our program forward," said Medolife CEO Dr. Arthur Mikaelian.
The acknowledgment by the FDA of the clinical trial conducted in the DR as a proof-of-concept for Escozine(R)'s therapeutic potential as a COVID-19 therapeutic is an important aspect of the response.
"Given the ever-changing landscape of COVID-19, we are pleased that the FDA recognizes that our original proposed study was a proof-of-concept design under our original Pre-IND submission," said Christina DiArcangelo, CEO and Founder of Affinity Bio Partners, a contracted clinical consultant for Medolife.
DiArcangelo has 24 years of experience in the global biotechnology, pharmaceutical, device, and nutraceutical industries and has worked on products that have received FDA approval on 25 pharmaceutical drugs.
While both the palliative and therapeutic potential of Escozine(R) were highlighted in the filing, the FDA recognized the potential therapeutic benefits of the drug, alluding to its ability to fight the COVID-19 virus, another important aspect of the response.
"Another interesting aspect of this Pre-IND filing is that we included both the therapeutic and palliative potential of Escozine in treating COVID-19," noted Medolife advisory board member and clinical adviser Dr. Annabelle Morgan. "This means that the drug could help reduce symptoms in patients who have the virus in addition to its potential benefit in fighting the virus itself. I am optimistic that the response seemed to point to its potential therapeutic benefit as well as its palliative."
Lead researcher on the Escozine(R) clinical trial program, Dr. Khalid Matalka, stated: "I am very pleased that the FDA acknowledged the results of our clinical trial on Escozine(R) as a COVID-19 therapeutic in the DR. It was an extremely positive outcome, where we saw that after four to five days of taking Escozine as a monotherapy, all COVID-19 positive clinical participants had a significant improvement and tested negative for the virus within a week time. The drug contains four small molecular peptides that block ion channels causing a multi-action effect on the SARS-CoV-2 pathogenesis as both a therapeutic and palliative potential drug."
"It is understandable that the FDA is paying close attention to the toxicological aspects of new drug applications, because excessive studies from vaccinations caused the FDA to be more cautious about the side-effects of the drugs, especially how they affect the body on a genetic level," added Dr. Mikaelian. "Fortunately, these additional studies will not add more time to our program than originally anticipated."
Also included in the response was a very detailed roadmap for the next phases of U.S. clinical trials with specific protocols. The amount of detail given in the guidelines will dramatically expedite the Company's timeline for preparing for the next steps of the clinical program.
"The FDA regularly provides the level of detail provided in our response to companies who have already passed the Pre-IND stage. We believe this is an indication of the level of confidence the FDA has in Escozine's potential for approval and will allow for more time in the market approval process," stated Dr. Mikaelian.
Christina DiArcangelo added: "The FDA has provided us with clinically meaningful endpoints and assistance in the design of future trials, including minor diversity and pediatric patients. By doing so, we have a clear understanding as to how to proceed forward, not only with our next study but with the development of the entire Escozine clinical program. This information is so valuable and will help us to expedite our program in a meaningful way. We are very grateful for the FDA's thorough guidance."
The Company plans to commence the additional toxicity studies requested in the response in the coming weeks with a short completion timeline. After that, the Company will file the data to the FDA, once again seeking approval of its Pre-IND, moving the Company closer to approval.
About Medolife Rx
Medolife Rx, Inc. is a global biotechnology company with operations in clinical research, manufacturing, and consumer products. Medolife Rx was created through the merger of Medolife, a private company founded by Dr. Arthur Mikaelian who pioneered the unlaying polarization technology that makes the Company's portfolio of pharmaceutical and nutraceutical products so effective, and Quanta, Inc., a direct-to-consumer wellness product portfolio company. The Company's lead clinical development programs include Escozine(R), a proprietary formulation consisting of small molecule peptides derived from Rhopalurus princeps scorpions, which is amplified by the Company's polarization technology and is being researched as a treatment of various indications, including COVID-19 and cancer. The Company has completed preclinical safety and efficacy research on Escozine(R) and is pursuing product registration and drug approval in various countries, including the United States and throughout Latin America.
Through its subsidiary QuantRx, Medolife manufactures and distributes consumer wellness products in high-impact consumer areas such as pain relief, beauty, and general wellness. QuantRx products are designed using Dr. Mikaelian's polarization technology, which applies advances in quantum biology to increase the potency of active ingredients. Ultimately, Quanta's mission is to deliver better, more effective ingredients to elevate product efficacy, reduce waste, and facilitate healthier, more sustainable consumption.
Beyond its own clinical and consumer applications, the polarization technology used by Medolife and its subsidiaries has many potential applications. From potentiating bio-ingredients, to producing more-effective carbon-trapping plants, to transformative anti-aging solutions, Medolife has the opportunity to upend how commercial and pharmaceutical products are made and increase their benefits, while decreasing their chemical concentration.
Forward-Looking Statements
Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995: This release contains statements that are forward-looking in nature which express the beliefs and expectations of management including statements regarding the Company's expected results of operations or liquidity; statements concerning projections, predictions, expectations, estimates or forecasts as to our business, financial and operational results and future economic performance; and statements of management's goals and objectives and other similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "estimate," "plan," "project," "continuing," "ongoing," "expect," "we believe," "we intend," "may," "will," "should," "could," and similar expressions. Such statements are based on current plans, estimates and expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. These factors and additional information are discussed in the Company's filings with the Securities and Exchange Commission and statements in this release should be evaluated in light of these important factors. Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
Contacts:
Tom Nelson
https://ir.quantrx.com/
480-326-8577
Kyle Porter
medolife@cmwmedia.com
858-264-6600
https://ml.globenewswire.com/media/dbe8fad7-b222-45ce-92ef-446b52583d6e/small/quanta-logo-png.png
https://ml.globenewswire.com/media/dbe8fad7-b222-45ce-92ef-446b52583d6e/small/quanta-logo-png.png
Maybe, NOTHING is wrong with it, everyone myself included has unfortunately learned to very skeptical… this however looks to be the real deal, and that’s scary to some … call me crazy but I have faith in QNTA like the little engine that could :) $ $ $ choo chooooo$$$
July 5 the product will be available.. right now it’s listed as pre-orders … the company is getting all their preverbal ducks in a row … paytience $$$
Let’s not start pointing political fingers at blue / red states … today’s QNTA news had a VERY curious quote about new fda I for asked for, specifically about dna … if they are now adding required data on dna specifically as a direct result of recent vaccinations pushed through … anyone wanting to pause and know more about a vaccine shouldn’t be shunned …instead we should be thrilled about the QNTA therapeutic positive results in combatting covid … it’s a scary virus for sure, and being vaccinated doesn’t mean one cannot contract the virus it’s just more hopeful you’ll not die from it or have as severe side effects from it. Ideally the vaccine will help your immune system ward off the virus all together - however, it is NOT full proof .. escozine could very well be the very thing that will be hailed as this centuries miracle drug …. And for all those around the world unable to obtain or unwilling to get vaccinated, let’s look at them as customers ;) Interesting quote from an article I’m reading
“Since adoption of COVID-19 vaccinations, the FDA altered its protocol for measuring toxicology to include studying it at the DNA level. As this is a newer development, the agency has asked Medolife to provide data in this regard. Medolife has the product and protocol necessary to complete these studies in short-order.”
https://www.globenewswire.com/news-release/2021/06/23/2251802/0/en/FDA-Accepts-COVID-19-Clinical-Study-and-Advises-on-Next-Steps-for-Pre-IND-Filing-by-Medolife-Rx.html
“Another interesting aspect of this Pre-IND filing is that we included both the therapeutic and palliative potential of Escozine in treating COVID-19,” noted Medolife advisory board member and clinical adviser Dr. Annabelle Morgan. “This means that the drug could help reduce symptoms in patients who have the virus in addition to its potential benefit in fighting the virus itself. I am optimistic that the response seemed to point to its potential therapeutic benefit as well as its palliative.”
Lead researcher on the Escozine® clinical trial program, Dr. Khalid Matalka, stated: “I am very pleased that the FDA acknowledged the results of our clinical trial on Escozine® as a COVID-19 therapeutic in the DR. It was an extremely positive outcome, where we saw that after four to five days of taking Escozine as a monotherapy, all COVID-19 positive clinical participants had a significant improvement and tested negative for the virus within a week time. The drug contains four small molecular peptides that block ion channels causing a multi-action effect on the SARS-CoV-2 pathogenesis as both a therapeutic and palliative potential drug.”
If one reads the article / response in full AND goes back and listens to the CC that was recorded, the dots are all lining up as they expected they would - based on the years of research data and covid trials they did already. IMO before summer is over we will see a huge shift upwards on the PPS https://www.globenewswire.com/news-release/2021/06/23/2251802/0/en/FDA-Accepts-COVID-19-Clinical-Study-and-Advises-on-Next-Steps-for-Pre-IND-Filing-by-Medolife-Rx.html
Some of Their sells were happily bought by me … I’m extremely long on this and heavily invested… QNTA has so many amazing things in the works and ready for market using their proven quantum biology science technology… it’s been said many times on this board but really truly this stock is like a unicorn or gem pick your own analogy Or simply put IMO exponential growth potential based on years of the QNTA scorpion studies / trials with outstanding positive results!!!
“We could not be more pleased with the response from the FDA, in its acknowledgment of our clinical trials on Escozine and its potential therapeutic benefit, as well as the very clear guidelines set forth in the response for moving our program forward,” said Medolife CEO Dr. Arthur Mikaelian.
https://www.globenewswire.com/news-release/2021/06/23/2251802/0/en/FDA-Accepts-COVID-19-Clinical-Study-and-Advises-on-Next-Steps-for-Pre-IND-Filing-by-Medolife-Rx.html
https://www.otcmarkets.com/stock/QNTA/news/story?e&id=1910917
IMO there is Exponential potential
Worth reading the article - Here is an Excerpt from this link … [{“The Company has completed preclinical safety and efficacy research on Escozine® and is pursuing product registration and drug approval in various countries, including the United States and throughout Latin America.
Through its subsidiary QuantRx, Medolife manufactures and distributes consumer wellness products in high-impact consumer areas such as pain relief, beauty, and general wellness. QuantRx products are designed using Dr. Mikaelian’s polarization technology, which applies advances in quantum biology to increase the potency of active ingredients. Ultimately, Quanta's mission is to deliver better, more effective ingredients to elevate product efficacy, reduce waste, and facilitate healthier, more sustainable consumption.
Beyond its own clinical and consumer applications, the polarization technology used by Medolife and its subsidiaries has many potential applications. From potentiating bio-ingredients, to producing more-effective carbon-trapping plants, to transformative anti-aging solutions, Medolife has the opportunity to upend how commercial and pharmaceutical products are made and increase their benefits, while decreasing their chemical concentration.”}]
Products are available July 5th… perhaps since the muscle rub is showing as pre order / available July 5th, I would speculate the push by promotions and endorsements would come out then too https://aeliastore.com/shop/pain/rubs/muscle-rub-tube-maximum-pain-relief/
Amen !!! Green sounds great. The fact the company seems to be tidying up all the books and making everything transparent all Makes for a strong foundation going forward ... once things all solidify then the US & international selling can take off.
I’m in the same boat Screwdriverx ..
it’s tough looking at 6 figure red.. HOWEVER I’m surprisingly not anxious about it, why? Because I too am in for the long haul, I refrained from the sellers it popped to o.20 awhile back because I’m looking at the (potential) big picture $$$. They are thus far doing all they said in the CC... laying out the ground work one step at time ... cheers to the longs, have a great weekend QNTA $$$
-when the ticker changes I think the stock will be in its glory, as will the investors (IMO that is ;)
Paytience $ QNTA all the pieces getting into place .. Lots of things coming online just as was told to us during the CC. I’m betting after July 5 (?) we will see upward trends as the Products are pre order and available in July https://aeliastore.com/shop/pain/rubs/muscle-rub-tin-maximum-pain-relief/
Exactly! NO drawback whatsoever.. imagine, Hawk has extreme wealth and subsequent disposable income to purchase the BEST most EFFECTIVE muscle rub .. clearly the product is effective - his endorsement is fantastic!! Surely he’s used to dealing with bruising, I think his testimonial is brilliant
https://www.google.com/amp/s/amp.tmz.com/2021/03/18/tony-hawk-breaks-down-in-tears-after-nailing-last-ever-ollie-540/
Hawk will make muscle rub cool for the adults who all still think we are teens still ... 50 & 60 no longer look like the age did when we were kids in the 1970s & 1980s. People in general are far more active into later ages then used to be .. it’s cool to have grey hair AND still surf, skate board & participate in extreme sports ... HOWEVER let’s face it in our 50s no one recovers like an 18 year old would .. Tony Hawk will make the QNTA Aelia muscle rub a hip product one that exudes youthfulness and pain relief meant for an active generation. When you think about endorsements one must look at the target audience / demographic / customer / and finances of said customer ... he’s very known by many with disposable income that use said income on extreme sports well into their grey hair days ;) and will be looking for hip muscle rub ... it’s just another brilliant play by QNTA
https://www.google.com/amp/s/amp.tmz.com/2021/03/18/tony-hawk-breaks-down-in-tears-after-nailing-last-ever-ollie-540/
Ultimately,Hawk is a good business choice - and also just the beginning of news to come ... celebrity endorsement was just one piece of the pie ... QNTA has a lot of irons in the fire with covid / cancer therapeutics etc .. Tony Hawk and Aelia are just one of the many facets to the gem QNTA. https://www.google.com/amp/s/www.businessinsider.com/tony-hawk-net-worth-lifestyle-career-investments-video-games-2020-5%3famp
{“Investors and consumers are encouraged to sign up for product updates at aeliastore.com/tony. The Company expects to introduce the newly branded line of products in the coming weeks.”}
https://www.globenewswire.com/news-release/2021/06/17/2248966/0/en/Medolife-Rx-Signs-Product-Endorsement-Agreement-With-Legendary-Skateboarder-Tony-Hawk.html
another great point : [{“the venom side of the business is pretty amazing... but I think most people on here are downplaying the other side of the business. their ability to polarized ingredients making them more potent is huge. it's hard to quantify outside of results but a few big contracts could turn into huge profits. I am excited about the company. I have a few million shares and won't be selling any time soon... GLTA”}] https://finance.yahoo.com/quote/QNTA/community/
“We could not be more pleased by the results of this research,” said Medolife CEO Dr. Arthur Mikaelian. “As we progress in our clinical research on Escozine®, where we are initially targeting product registration and approval for treatment of COVID-19, we are conducting ongoing research on its potential therapeutic benefits as a treatment for various other indications, including many types of cancer. In this study, our drug completely eliminated the cell lines of two types of cancer in three samples. These results are not just exciting, they could be the precipice for what could become an effective treatment for one of the largest health issues in the world. Beyond proving the peptides’ ability to eradicate cancer cell lines, the study also showed how effective our polarization technology is on increasing efficacy. With results like these, I could not be more confident in Escozine® as a viable treatment for a variety of health issues and we are so proud to continue to push it through clinical trials around the world.”
The Company is conducting concurrent clinical studies on Escozine® around the world in countries such as the Dominican Republic and the United States. It is seeking product registration in the Dominican Republic for treatment of COVID-19, where it recently announced positive efficacy and safety results on over 500 patients. Additionally, it has filed data on Escozine® with the US Food and Drug Administration (FDA) as a Pre-Investigational New Drug (PIND #150335) as a COVID-19 therapeutic and is hoping to receive a response in short order. Medolife utilizes a patented polarization technology in all of its clinical drug candidates and nutraceutical consumer products that increase the potency of single molecules and complex compounds.
https://www.otcmarkets.com/stock/QNTA/news/story?e&id=1845665
https://abs-sustainabledevelopment.net/wp-content/uploads/2019/05/Dominican-Republic-1.pdf
:) lots of good things about this company
https://m.insidertracking.com/company-news?ticker=QNTA
I’m not hanging on hopes of news ... of course like everyone I’m certainly watching for it as I own quite a sum of this stock ... I’ve researched the company and I’m patiently waiting. I’ve looked at every angle - it’s astonishing to me the stock isn’t rising, honestly the fundamentals are all there :)
Thanks for sharing ... instead of speculation and spinning wheels best to just flat out ask - I’ll second his reply, o hope soon too ;) in the mean time I’m holding strong QNTA our child was born a week over due .. this has that same feeling ... hurry up and uncomfortably wait